Lisa Yañez, CEO of Aerami Therapeutics, a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary conditions, discusses the company’s plans to advance AER-901, a drug-device combination comprised of imatinib for inhalation and the FOX ® nebulizer into a Phase 2 trial in 2023. She talks about the approach to clinical development in pulmonary arterial hypertension (PAH), a rare and progressive disease with no cure or currently approved therapies, and the new developments and anticipated milestones related to Aerami’s pipeline and AER-901 development program.
In December 2022, Lisa Yañez was appointed CEO of Aerami Therapeutics. Ms. Yañez joined the Aerami leadership team in early 2022 as COO, helping to oversee important milestones for the company’s inhaled imatinib program, AER-901.
Ms. Yañez has more than 25 years of leadership experience at leading pharmaceutical and biotechnology companies, including Merck, Genentech, GSK, and most recently, United Therapeutics and Acceleron Pharma. At United Therapeutics, Ms. Yañez led the multi-billion-dollar PAH franchise that includes five of the fifteen currently FDA-approved therapies for PAH. At Acceleron, Ms. Yañez spearheaded initiatives that engaged clinical development, preclinical research and external medical experts to build a differentiated pulmonary franchise strategy and PAH development program for a potential reverse remodeling therapy.
Ms. Yañez has engaged throughout her careers across the product life cycle, establishing expertise ranging from early product planning to launch and life cycle strategy, as well as across treatment categories including pulmonary, oncology, neurology, immunology, cardiovascular and rheumatology.